Washington Report

May 01, 2011
Pharmaceutical Executive
Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies
Apr 01, 2011
Pharmaceutical Executive
Courts, Congress review policies and programs shaping drug costs and access
Mar 01, 2011
Pharmaceutical Executive
FDA's Sentinel Initiative raises broader questions about tapping patient information and health IT for comparative studies in drug development
Feb 01, 2011
Pharmaceutical Executive
The Three Cs could be taxing on FDA resources as the new Congress brings stiffer oversight and leadership revisions to the agency
Jan 01, 2011
Pharmaceutical Executive
Pharma companies will assess health reform, negotiate user fees and keep an eye on federal prosecutors in the year ahead
Dec 01, 2010
Pharmaceutical Executive
Republican gains in Congress create uncertainty for health reform, drug regulation, and biomedical research
Nov 01, 2010
Pharmaceutical Executive
PCORI is independent and transparent and likely to alter methods for assesssing the value of new therapies
Oct 01, 2010
Pharmaceutical Executive
Health reform requires detailed tracking and full disclosure of fees to docs for marketing and research
Sep 01, 2010
Pharmaceutical Executive
FDA seeks to regulate genetic tests more actively, while encouraging diagnostic development
Jul 01, 2010
Pharmaceutical Executive
Drug prices, doctor payments, and FDA regulatory decisions are candidates for expanded disclosure.
native1_300x100
lorem ipsum